5-(2-(1-methyl-1H-pyrazol-4-yl)-4-(trifluoromethyl)phenyl)-N-(1,2,4-thiadiazol-5-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide | 1454666-36-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 5-(2-(1-methyl-1H-pyrazol-4-yl)-4-(trifluoromethyl)phenyl)-N-(1,2,4-thiadiazol-5-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide
• 英文别名: 5-[2-(1-methylpyrazol-4-yl)-4-(trifluoromethyl)phenyl]-N-(1,2,4-thiadiazol-5-yl)-3,4-dihydro-1H-isoquinoline-2-sulfonamide
• CAS: 1454666-36-4
• 化学式: C₂₂H₁₉F₃N₆O₂S₂
• 分子量: 520.559
• InChiKey: BGYNZTFWBOFPBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  130
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• [EN] SULFAMIDE SODIUM CHANNEL INHIBITORS<br/>[FR] INHIBITEURS SULFAMIDES DES CANAUX DE SODIUM
  申请人：AMGEN INC

  公开号：WO2013134518A1

  公开（公告）日：2013-09-12

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了式I的化合物或其药学上可接受的盐，这些化合物是电压门控钠通道的抑制剂，特别是Nav 1.7。这些化合物对于治疗通过抑制钠通道可治疗的疾病，如疼痛障碍，是有用的。还提供了含有本发明化合物的药物组合物。
• BENZODIOXANES IN COMBINATION WITH OTHER ACTIVES FOR INHIBITING LEUKOTRIENE PRODUCTION
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2822941A1

  公开（公告）日：2015-01-14
• US9051311B2
  申请人：——

  公开号：US9051311B2

  公开（公告）日：2015-06-09
• [EN] BENZODIOXANES IN COMBINATION WITH OTHER ACTIVES FOR INHIBITING LEUKOTRIENE PRODUCTION<br/>[FR] BENZODIOXANNES EN COMBINAISON AVEC D'AUTRES PRINCIPES ACTIFS POUR L'INHIBITION DE LA PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013131901A1

  公开（公告）日：2013-09-12

  The present invention relates to a combination comprising compounds of formula (I): wherein R1to R3, A, X and n are as defined herein, and an additional active agent. The present invention also relates pharmaceutical compositions comprising these combinations, and methods of using these combinations to treat various diseases and disorders.